Publicaciones en las que colabora con Matias Antonio Ávila Zaragozá (12)

2022

  1. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376

2018

  1. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

    Cell Death and Disease, Vol. 9, Núm. 10

  2. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1468-1477

2009

  1. Amphiregulin Induces the Alternative Splicing of p73 Into Its Oncogenic Isoform ΔEx2p73 in Human Hepatocellular Tumors

    Gastroenterology, Vol. 137, Núm. 5

  2. Inflammation and liver cancer: New molecular links

    Annals of the New York Academy of Sciences

  3. The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression

    Journal of Hepatology, Vol. 51, Núm. 6, pp. 1010-1020

  4. The epidermal growth factor receptor: A link between inflammation and liver cancer

    Experimental Biology and Medicine

  5. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy

    Cancer Research, Vol. 69, Núm. 4, pp. 1358-1367

2008

  1. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis

    Hepatology, Vol. 48, Núm. 4, pp. 1251-1261

2007

  1. Amphiregulin: A new growth factor in hepatocarcinogenesis

    Cancer Letters, Vol. 254, Núm. 1, pp. 30-41

2006

  1. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells

    Cancer Research, Vol. 66, Núm. 12, pp. 6129-6138